Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 60 articles:
HTML format



Single Articles


    October 2024
  1. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1675-1682.
    PubMed     Abstract available


  2. CHU X, Tian W, Ning J, Zhou R, et al
    Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis.
    J Natl Cancer Inst. 2024;116:1571-1586.
    PubMed     Abstract available


    September 2024
  3. PROSPER AE, Lin Y, Aberle DR
    Lung cancer screening with low-dose computed tomography-where do we go from here?
    J Natl Cancer Inst. 2024 Sep 16:djae197. doi: 10.1093.
    PubMed    


    August 2024
  4. LIU Q, Medina HN, Koru-Sengul T, Rodriguez E, et al
    Intra-Ethnic and Geographic Disparities in Stage at Diagnosis for Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2024 Aug 21:djae199. doi: 10.1093.
    PubMed     Abstract available


  5. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed     Abstract available


    June 2024
  6. ZHANG EY, Cheung LC, Katki HA, Graubard BI, et al
    The risk and benefit profiles of US eligible lung cancer screening attendees vs. non-attendees.
    J Natl Cancer Inst. 2024 Jun 27:djae148. doi: 10.1093.
    PubMed     Abstract available


  7. HENDERSON LM, Durham DD, Gruden J, Pritchard M, et al
    Comparing characteristics of individuals screened for lung cancer with 2021 versus 2013 USPSTF recommendations.
    J Natl Cancer Inst. 2024 Jun 24:djae141. doi: 10.1093.
    PubMed     Abstract available


  8. WU X, Zhang B
    RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 8:djae130. doi: 10.1093.
    PubMed    


  9. TAKI T, Ishii G
    RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 7:djae131. doi: 10.1093.
    PubMed    


  10. SCHUZ J, Kovalevskiy E, Olsson A, Moissonnier M, et al
    Cancer mortality in chrysotile miners and millers, Russian Federation: main results (Asbest Chrysotile Cohort-Study).
    J Natl Cancer Inst. 2024;116:866-875.
    PubMed     Abstract available


  11. UPRETY D, Seaton R, Hadid T, Mamdani H, et al
    Racial and socioeconomic disparities in survival among patients with metastatic Non-Small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 3:djae118. doi: 10.1093.
    PubMed     Abstract available


    March 2024
  12. FUCITO LM, Palmer AM, Baldassarri SR
    A new perspective on mitigating lung cancer risks through smoking cessation and reduction.
    J Natl Cancer Inst. 2024 Mar 18:djae044. doi: 10.1093.
    PubMed    


  13. NAGASAKI Y, Taki T, Nomura K, Tane K, et al
    Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Mar 8:djae053. doi: 10.1093.
    PubMed     Abstract available


    February 2024
  14. MOEN EL, Schmidt RO, Onega T, Brooks GA, et al
    Association between a network-based physician linchpin score and cancer patient mortality: a SEER-Medicare analysis.
    J Natl Cancer Inst. 2024;116:230-238.
    PubMed     Abstract available


  15. MEERNIK C, Raveendran Y, Kolarova M, Rahman F, et al
    Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review.
    J Natl Cancer Inst. 2024 Feb 6:djae026. doi: 10.1093.
    PubMed     Abstract available


    January 2024
  16. GUTIERREZ-TORRES DS, Kim S, Albanes D, Weinstein SJ, et al
    Changes in smoking use and subsequent lung cancer risk in the ATBC study.
    J Natl Cancer Inst. 2024 Jan 25:djae012. doi: 10.1093.
    PubMed     Abstract available


    December 2023
  17. SHIELS MS, Graubard BI, McNeel TS, Kahle L, et al
    Trends in smoking-attributable and smoking-unrelated lung cancer death rates in the U.S., 1991-2018.
    J Natl Cancer Inst. 2023 Dec 9:djad256. doi: 10.1093.
    PubMed     Abstract available


  18. BILLINGY NE, Tromp VNMF, Aaronson NK, Hoek RJA, et al
    Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial.
    J Natl Cancer Inst. 2023;115:1515-1525.
    PubMed     Abstract available


  19. ZUMSTEG ZS, Luu M, Rosenberg PS, Elrod JK, et al
    Global epidemiologic patterns of oropharyngeal cancer incidence trends.
    J Natl Cancer Inst. 2023;115:1544-1554.
    PubMed     Abstract available


    November 2023
  20. LEHRER S, Rheinstein PH
    Re: Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancers.
    J Natl Cancer Inst. 2023;115:1427-1428.
    PubMed    


  21. LU K, Wang HC, Tu YC, Chang CC, et al
    Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer.
    J Natl Cancer Inst. 2023;115:1383-1391.
    PubMed     Abstract available


  22. EVANS JV, Suman S, Goruganthu MUL, Tchekneva EE, et al
    Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.
    J Natl Cancer Inst. 2023;115:1404-1419.
    PubMed     Abstract available


    September 2023
  23. KHODAYARI MOEZ E, Warkentin MT, Brhane Y, Lam S, et al
    Circulating proteome for pulmonary nodule malignancy.
    J Natl Cancer Inst. 2023;115:1060-1070.
    PubMed     Abstract available


    August 2023
  24. RAPHAEL J, Richard L, Lam M, Blanchette P, et al
    Early mortality in patients with cancer treated with immune checkpoint inhibitors in routine practice.
    J Natl Cancer Inst. 2023;115:949-961.
    PubMed     Abstract available


    July 2023
  25. CHANG A, Flores RM, Taioli E
    Unequal Racial Distribution of Immunotherapy for Late-Stage Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2023 Jul 8:djad132. doi: 10.1093.
    PubMed     Abstract available


    June 2023
  26. MILANO MT, Salama JK, Chmura SJ
    Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy?
    J Natl Cancer Inst. 2023;115:605-607.
    PubMed    


  27. WANG XS, Bai YF, Verma V, Yu RL, et al
    Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2023;115:742-748.
    PubMed     Abstract available


  28. FENG X, Wu WY, Onwuka JU, Haider Z, et al
    Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools.
    J Natl Cancer Inst. 2023 Jun 1:djad071. doi: 10.1093.
    PubMed     Abstract available


    May 2023
  29. CARROLL NM, Burnett-Hartman AN, Rendle KA, Neslund-Dudas CM, et al
    Smoking status and the association between patient-level factors and survival among lung cancer patients.
    J Natl Cancer Inst. 2023 May 25:djad098. doi: 10.1093.
    PubMed     Abstract available



  30. Correction to: Randomized trial of First-Line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-Mutated Non-Small cell lung cancer.
    J Natl Cancer Inst. 2023 May 18:djad084. doi: 10.1093.
    PubMed    


  31. RUSTHOVEN CG, Staley AW, Gao D, Yomo S, et al
    Comparison of First-Line Radiosurgery for Small-Cell and Non-Small Cell Lung Cancer Brain Metastases (Cross-FIRE).
    J Natl Cancer Inst. 2023 May 4:djad073. doi: 10.1093.
    PubMed     Abstract available


    April 2023
  32. UNGER JM, Qian L, Redman MW, Tavernier SS, et al
    Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
    J Natl Cancer Inst. 2023;115:437-446.
    PubMed     Abstract available


  33. OH DL, Schumacher K, Yang J, Wang K, et al
    Disparities in cancer incidence by rurality in California.
    J Natl Cancer Inst. 2023;115:385-393.
    PubMed     Abstract available


    February 2023
  34. SELBY K, Sedki M, Levine E, Kamineni A, et al
    Test performance metrics for breast, cervical, colon and lung cancer screening: a systematic review.
    J Natl Cancer Inst. 2023 Feb 8:djad028. doi: 10.1093.
    PubMed     Abstract available


    December 2022
  35. SIRUFO MM, Ginaldi L, De Martinis M
    RE: Sociodemographic Survival Disparities for Lung Cancer in the United States, 2000-2016.
    J Natl Cancer Inst. 2022 Dec 19:djac235. doi: 10.1093.
    PubMed    


    November 2022
  36. HEIDEN BT, Eaton DB, Chang SH, Yan Y, et al
    Association between imaging surveillance frequency and outcomes following surgical treatment of early-stage lung cancer.
    J Natl Cancer Inst. 2022 Nov 29:djac208. doi: 10.1093.
    PubMed     Abstract available


  37. LI M, Liao K, Chen AJ, Cascone T, et al
    Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer.
    J Natl Cancer Inst. 2022 Nov 8. pii: 6809139. doi: 10.1093.
    PubMed     Abstract available


  38. DI FEDERICO A, De Giglio A, Gelsomino F, Sperandi F, et al
    Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis.
    J Natl Cancer Inst. 2022 Nov 2. pii: 6794208. doi: 10.1093.
    PubMed     Abstract available


    October 2022
  39. YOU S, Kim M, Hoi XP, Lee YC, et al
    Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy.
    J Natl Cancer Inst. 2022;114:1380-1391.
    PubMed     Abstract available


    September 2022
  40. WARKENTIN MT, Tammemagi MC, Espin-Garcia O, Budhathoki S, et al
    Lung Cancer Absolute Risk Models for Mortality in Asian Population using China Kadoorie Biobank.
    J Natl Cancer Inst. 2022 Sep 9. pii: 6694851. doi: 10.1093.
    PubMed     Abstract available


  41. PELLINEN T, Paavolainen L, Martin-Bernabe A, Papatella Araujo R, et al
    Fibroblast subsets in non-small cell lung cancer: associations with survival, mutations, and immune features.
    J Natl Cancer Inst. 2022 Sep 9. pii: 6694853. doi: 10.1093.
    PubMed     Abstract available


    August 2022
  42. SEDANI AE, Davis OC, Clifton SC, Campbell JE, et al
    Facilitators and Barriers to Implementation of Lung Cancer Screening: A Framework Driven Systematic Review.
    J Natl Cancer Inst. 2022 Aug 22. pii: 6673083. doi: 10.1093.
    PubMed     Abstract available


  43. VOGTMANN E, Hua X, Yu G, Purandare V, et al
    The oral microbiome and lung cancer risk: An analysis of 3 prospective cohort studies.
    J Natl Cancer Inst. 2022 Aug 5. pii: 6656358. doi: 10.1093.
    PubMed     Abstract available


    July 2022
  44. BROUWER AF, Engle JM, Jeon J, Meza R, et al
    Sociodemographic survival disparities for lung cancer in the United States, 2000-2016.
    J Natl Cancer Inst. 2022 Jul 22. pii: 6648464. doi: 10.1093.
    PubMed     Abstract available


  45. TAYLOR KL, Williams RM, Li T, Luta G, et al
    A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting.
    J Natl Cancer Inst. 2022 Jul 12. pii: 6633937. doi: 10.1093.
    PubMed     Abstract available


    June 2022
  46. CASTILHO JL, Bian A, Jenkins CA, Shepherd BE, et al
    CD4/CD8 Ratio and Cancer Risk Among Adults With HIV.
    J Natl Cancer Inst. 2022;114:854-862.
    PubMed     Abstract available


    May 2022
  47. GABRIEL AAG, Atkins JR, Penha RCC, Smith-Byrne K, et al
    Genetic analysis of lung cancer and the germline impact on somatic mutation burden.
    J Natl Cancer Inst. 2022 May 2. pii: 6576636. doi: 10.1093.
    PubMed     Abstract available


    April 2022

  48. Expression of Concern to: Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2022 Apr 1. pii: 6561908. doi: 10.1093.
    PubMed    


    February 2022
  49. TANAKA I, Dayde D, Tai MC, Mori H, et al
    SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas.
    J Natl Cancer Inst. 2022;114:290-301.
    PubMed     Abstract available


    December 2021
  50. CHOI E, Luo SJ, Aredo JV, Backhus LM, et al
    The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer.
    J Natl Cancer Inst. 2021 Dec 10. pii: 6459177. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  51. ISLAMI F, Ward EM, Sung H, Cronin KA, et al
    Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics.
    J Natl Cancer Inst. 2021;113:1648-1669.
    PubMed     Abstract available


  52. GAVRIELATOU N, Shafi S, Gaule P, Rimm DL, et al
    PD-L1 Expression Scoring: Noninterchangeable, Noninterpretable, Neither, or Both.
    J Natl Cancer Inst. 2021;113:1613-1614.
    PubMed    


    August 2021
  53. HOPKINS AM, Kichenadasse G, Logan JM, Rowland A, et al
    RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2021 Aug 27. pii: 6358733. doi: 10.1093.
    PubMed    


  54. ZHAO W, Zhu B, Hutchinson A, Pesatori AC, et al
    Clinical Implications of Inter- and Intra-Tumor Heterogeneity of Immune Cell Markers in Lung Cancer.
    J Natl Cancer Inst. 2021 Aug 17. pii: 6353611. doi: 10.1093.
    PubMed     Abstract available


  55. DEROUEN MC, Canchola AJ, Thompson CA, Jin A, et al
    Incidence of Lung Cancer Among Never-Smoking Asian American, Native Hawaiian, and Pacific Islander Females.
    J Natl Cancer Inst. 2021 Aug 4. pii: 6338453. doi: 10.1093.
    PubMed     Abstract available


    July 2021
  56. CHOI E, Sanyal N, Ding VY, Gardner RM, et al
    Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer.
    J Natl Cancer Inst. 2021 Jul 13. pii: 6320070. doi: 10.1093.
    PubMed     Abstract available


    June 2021
  57. WANG X, Ricciuti B, Alessi JV, Nguyen T, et al
    Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2021 Jun 11. pii: 6296846. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  58. VERHOEVEN DC, Chollette V, Lazzara EH, Shuffler ML, et al
    The Anatomy and Physiology of Teaming in Cancer Care Delivery: A Conceptual Framework.
    J Natl Cancer Inst. 2021;113:360-370.
    PubMed     Abstract available


    December 2020
  59. MITCHELL AP, Bach PB
    Use of Positron Emission Tomography Imaging: Another Nonbiological Source of Racial Disparities in US Cancer Care.
    J Natl Cancer Inst. 2020;112:1177-1178.
    PubMed    


    July 2020
  60. TAKVORIAN SU, Balogh E, Nass S, Valentin VL, et al
    Developing and Sustaining an Effective and Resilient Oncology Careforce: Opportunities for Action.
    J Natl Cancer Inst. 2020;112:663-670.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.